Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
Public ClinicalTrials.gov record NCT02400346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Study identification
- NCT ID
- NCT02400346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Enrollment
- 132 participants
Conditions and interventions
Conditions
Interventions
- ADT Drug
- Adjunct brexpiprazole Drug
Drug
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2015
- Primary completion
- May 31, 2016
- Completion
- May 31, 2016
- Last update posted
- Aug 9, 2017
2015 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| US012 | Arcadia | California | — | — |
| US004 | Miami | Florida | — | — |
| US007 | Orlando | Florida | — | — |
| US006 | Smyrna | Georgia | — | — |
| US002 | O'Fallon | Missouri | — | — |
| US010 | Toms River | New Jersey | — | — |
| US005 | New York | New York | — | — |
| US008 | New York | New York | — | — |
| US003 | Staten Island | New York | — | — |
| US014 | Oklahoma City | Oklahoma | — | — |
| US009 | Allentown | Pennsylvania | — | — |
| US001 | Memphis | Tennessee | — | — |
| US011 | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02400346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2017 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02400346 live on ClinicalTrials.gov.